These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 26329151

  • 21. Gaucher disease and its treatment options.
    Bennett LL, Mohan D.
    Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
    [Abstract] [Full Text] [Related]

  • 22. [Advances in the specific treatments of Gaucher disease].
    Meng Y.
    Zhonghua Nei Ke Za Zhi; 2024 Jul 01; 63(7):702-711. PubMed ID: 38951097
    [Abstract] [Full Text] [Related]

  • 23. [Gaucher disease].
    Ohashi T.
    Nihon Rinsho; 1995 Dec 01; 53(12):2943-6. PubMed ID: 8577040
    [Abstract] [Full Text] [Related]

  • 24. [Gaucher disease].
    Timonen T, Möttönen M, Nousiainen T, Herva R, Savolainen ER.
    Duodecim; 2005 Dec 01; 121(19):2068-76. PubMed ID: 16300295
    [No Abstract] [Full Text] [Related]

  • 25. [Epidemiologic, clinical, biological and therapeutic aspects of Gaucher disease].
    Stirnemann J, Caubel I, Kettaneh A, Fain O, Belmatoug N.
    Presse Med; 2003 Mar 22; 32(11):503-11. PubMed ID: 12733391
    [Abstract] [Full Text] [Related]

  • 26. The presence of an autologous marrow stromal cell layer increases glucocerebrosidase gene transduction of long-term culture initiating cells (LTCICs) from the bone marrow of a patient with Gaucher disease.
    Wells S, Malik P, Pensiero M, Kohn DB, Nolta JA.
    Gene Ther; 1995 Oct 22; 2(8):512-20. PubMed ID: 8593601
    [Abstract] [Full Text] [Related]

  • 27. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
    Marshall J, McEachern KA, Chuang WL, Hutto E, Siegel CS, Shayman JA, Grabowski GA, Scheule RK, Copeland DP, Cheng SH.
    J Inherit Metab Dis; 2010 Jun 22; 33(3):281-9. PubMed ID: 20336375
    [Abstract] [Full Text] [Related]

  • 28. [Pathogenic mechanism and therapies for Gaucher's disease].
    Liu LY, Du SC, Zhang J, Ma D.
    Yi Chuan; 2015 Jun 22; 37(6):510-6. PubMed ID: 26351046
    [Abstract] [Full Text] [Related]

  • 29. Correction of the enzyme deficiency in hematopoietic cells of Gaucher patients using a clinically acceptable retroviral supernatant transduction protocol.
    Xu L, Stahl SK, Dave HP, Schiffmann R, Correll PH, Kessler S, Karlsson S.
    Exp Hematol; 1994 Feb 22; 22(2):223-30. PubMed ID: 8299741
    [Abstract] [Full Text] [Related]

  • 30. Attempt at enzyme replacement in Gaucher disease by renal transplantation.
    Groth CG, Collste H, Dreborg S, Håkansson G, Lundgren G, Svennerholm L.
    Birth Defects Orig Artic Ser; 1980 Feb 22; 16(1):475-90. PubMed ID: 6778533
    [No Abstract] [Full Text] [Related]

  • 31. Gaucher disease. Unusual presentation and mini-review.
    Rizk TM, Ariganjoye RO, Alsaeed GI.
    Neurosciences (Riyadh); 2015 Jul 22; 20(3):271-6. PubMed ID: 26166597
    [Abstract] [Full Text] [Related]

  • 32. Does enzyme replacement therapy enhance brain-derived neurotrophic factor expression in Gaucher disease?
    Vairo F, Sperb-Ludwig F, Wilke M, Michellin-Tirelli K, Netto C, Camargo Neto E, Schwartz IV.
    J Neuroimmunol; 2015 Jun 15; 283():63. PubMed ID: 26004158
    [No Abstract] [Full Text] [Related]

  • 33. Gaucher disease: a lysosomal neurodegenerative disorder.
    Huang WJ, Zhang X, Chen WW.
    Eur Rev Med Pharmacol Sci; 2015 Apr 15; 19(7):1219-26. PubMed ID: 25912581
    [Abstract] [Full Text] [Related]

  • 34. How we manage Gaucher Disease in the era of choices.
    Revel-Vilk S, Szer J, Mehta A, Zimran A.
    Br J Haematol; 2018 Aug 15; 182(4):467-480. PubMed ID: 29808905
    [Abstract] [Full Text] [Related]

  • 35. Bone marrow transplantation in Gaucher's disease: effect of mixed chimeric state.
    Chan KW, Wong LT, Applegarth D, Davidson AG.
    Bone Marrow Transplant; 1994 Aug 15; 14(2):327-30. PubMed ID: 7994251
    [Abstract] [Full Text] [Related]

  • 36. Analysis of the pre-retinal opacities in Gaucher Disease using spectral domain optical coherent tomography.
    Sheck LH, Wilson CJ, Vincent AL.
    Ophthalmic Genet; 2012 Dec 15; 33(4):253-6. PubMed ID: 22950450
    [Abstract] [Full Text] [Related]

  • 37. Hematopoietic stem cell transplantation or enzyme replacement therapy in Gaucher disease type 3.
    Høj A, Ørngreen MC, Naume MM, Lund AM.
    Mol Genet Metab; 2024 Aug 15; 142(4):108515. PubMed ID: 38909587
    [Abstract] [Full Text] [Related]

  • 38. Engineering monocyte/macrophage-specific glucocerebrosidase expression in human hematopoietic stem cells using genome editing.
    Scharenberg SG, Poletto E, Lucot KL, Colella P, Sheikali A, Montine TJ, Porteus MH, Gomez-Ospina N.
    Nat Commun; 2020 Jul 03; 11(1):3327. PubMed ID: 32620863
    [Abstract] [Full Text] [Related]

  • 39. Gaucher disease: from fundamental research to effective therapeutic interventions.
    de Fost M, Aerts JM, Hollak CE.
    Neth J Med; 2003 Jan 03; 61(1):3-8. PubMed ID: 12688562
    [Abstract] [Full Text] [Related]

  • 40. Recent advances in treatment approaches to Gaucher disease.
    Elstein D.
    Curr Pharm Biotechnol; 2011 Jun 03; 12(6):854-60. PubMed ID: 21235447
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.